Journals / Türk Kardiyoloji Derneği Arşivi / 2011 / Cilt: 39 - Sayı: 2

Metabolik sendromu olan hastalarda artmış serum gama-glutamiltransferaz düzeyi

İncreased serum gamma-glutamyltransferase activity in patients with metabolic syndrome

Pages
122–128
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This increased GGT level might be a marker of increased oxidative stress and premature atherosclerosis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Accumulating data indicate that serum gammaglutamyltransferase (GGT) activity represents a true marker of atherosclerotic cardiovascular disease and has prognostic importance.
📊
Key Findings & Data:Study design: We enrolled 232 patients (mean age 60.4 years) from our outpatient cardiology clinic, 117 with and 115 without MetS (control group) as defined by the ATP-III criteria.
💡
Conclusion & Impact:This increased GGT level might be a marker of increased oxidative stress and premature atherosclerosis
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Accumulating data indicate that serum gammaglutamyltransferase (GGT) activity represents a true marker of atherosclerotic cardiovascular disease and has prognostic importance. In this study, we sought to evaluate serum GGT activity in patients with metabolic syndrome (MetS). Study design: We enrolled 232 patients (mean age 60.4 years) from our outpatient cardiology clinic, 117 with and 115 without MetS (control group) as defined by the ATP-III criteria. The results of serum liver function tests including serum GGT and C-reactive protein (CRP) levels were compared between the two groups. Results: The two groups were similar with regard to age, sex, smoking, and family history of coronary artery disease (p>0.05). The prevalences of hypertension and dyslipidemia were significantly higher in patients with MetS. Compared with controls, patients with MetS had significantly higher serum GGT [(median 21, interquartile range (16-33) vs. 19 (14-26) U/l; p=0.008] and C-reactive protein levels [6.2 (3.6- 9.4) vs. 5.0 (3.1-7.0) U/l; p=0.044]. A high GGT activity (>40 U/l) was determined in 14.5% of the patients with MetS and in 4.4% of the control subjects (p=0.012). Serum GGT level showed significant correlations with MetS (r=0.24, p=0.001), CRP (r=0.20, p=0.003), triglyceride (r=0.18, p=0.006), HDL cholesterol (r=-0.19, p=0.004), aspartate aminotransferase (r=0.15, p=0.02), alanine aminotransferase (r=0.32, p=0.001), and alkaline phosphatase (r=0.16, p=0.01). This significant association continued only for MetS (β=-0.25, p=0.03), HDL cholesterol (β=-0.18, p=0.03), and alkaline phosphatase (β=0.17, p=0.01) in multivariate regression analysis. Conclusion: Our findings suggest that patients with MetS have higher serum GGT and CRP levels compared with controls. This increased GGT level might be a marker of increased oxidative stress and premature atherosclerosis

Özet

Amaç: Giderek artan veriler serum gama-glutamiltransferaz (GGT) düzeyinin aterosklerotik kardiyovasküler hastalık için gerçek bir belirteç olduğunu ve prognostik değer taşıdığını göstermektedir. Bu çalışmada metabolik sendromu (MetS) olan hastalarda GGT düzeyinin incelenmesi amaçlandı. Çalışma planı: Kardiyoloji polikliniğine başvuran 232 hasta (117 MetS, 115 kontrol; ort. yaş 60.4) çalışmaya alındı. Metabolik sendrom tanısı ATP III ölçütlerine göre kondu. Hasta ve kontrol grubunun GGT dahil karaciğer fonksiyon testleri sonuçları ve C-reaktif protein (CRP) düzeyleri karşılaştırıldı. Bulgular: İki grup yaş, cinsiyet, sigara içme ve ailede koroner arter hastalığı öyküsü açısından benzerdi (p>0.05). Hipertansiyon ve hiperlipidemi sıklığı MetS grubunda daha yüksek idi. Kontrol grubuyla karşılaştırıldığında, MetS olan hastalarda serum GGT [medyan 21, çeyreklerarası aralık (16-33) ve 19 (14-26) U/l; p=0.008] ve C-reaktif protein [6.2 (3.6-9.4) ve 5.0 (3.1-7.0) U/l; p=0.044] düzeyleri anlamlı derecede yüksek saptandı. Yüksek GGT aktivitesi (>40 U/l) MetS grubunda %14.5 oranında, kontrol grubunda %4.4 oranında görüldü (p=0.012). Serum GGT düzeyi şu parametrelerle anlamlı ilişki gösterdi: MetS (r=0.24, p=0.001), CRP (r=0.20, p=0.003), trigliserit (r=0.18, p=0.006), HDLkolesterol (r=-0.19, p=0.004), aspartat aminotransferaz (r=0.15, p=0.02), alanin aminotransferaz (r=0.32, p=0.001) ve alkalin fosfataz (r=0.16, p=0.01). Çokdeğişkenli regresyon analizinde bu anlamlılık sadece MetS (β=-0.25, p=0.03), HDL-kolesterol (β=-0.18, p=0.03) ve alkalin fosfataz (β=0.17, p=0.01) için vardı. Sonuç: Bulgularımız MetS olan hastalarda serum GGT ve CRP düzeylerinin yüksek olduğunu göstermektedir. Artmış GGT düzeyi MetS’li olgularda artmış oksidatif stresin ve erken aterosklerozun bir belirteci olabilir.

🔖

Cite This Article

YILDIRIR, A., ÖZİN, B., AYDINALP, A., DEMİR, Ö., MÜDERRİSOĞLU, H., BOZBAŞ, H., ULUS, T., KARAÇAĞLAR, E., EROĞLU, S. (2022). Metabolik sendromu olan hastalarda artmış serum gama-glutamiltransferaz düzeyi. Türk Kardiyoloji Derneği Arşivi, Cilt: 39 - Sayı: 2, 122–128. https://ajindex.com/articles/633212

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Kugelman A, Choy HA, Liu R, Shi MM, Gozal E, Forman HJ. Gamma-Glutamyl transpeptidase is increased by oxidative stress in rat alveolar L2 epithelial cells. Am J Respir Cell Mol Biol 1994;11:586-92
  2. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al. Gamma-glutamyltransferase and diabetes-a 4 year follow-up study. Diabetologia 2003;46:359-64
  3. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27:1427-32
  4. Wannamethee G, Ebrahim S, Shaper AG. Gammaglutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995;142:699-708
  5. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50
  6. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995;9:101-5
  7. Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003;49:1358-66
  8. Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med 2003;254:287-95
  9. Meisinger C, Löwel H, Heier M, Schneider A, Thorand B; KORA Study Group. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005;258:527-35
  10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
  11. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998;21:732-7
  12. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-rea